ArticleFrontiers in medicine2026
Efficacy and safety of different immunosuppressive agents in patients with calcineurin inhibitor-dependent primary membranous nephropathy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy and safety of rituximab (RTX), cyclophosphamide (CTX), and tripterygium glycosides (TII) as conversion therapies in patients with calcineurin inhibitor (CNI)-dependent primary membranous nephropathy (PMN), and to evaluate their ability to induce clinical and immunological remission and facilitate CNI withdrawal. Methods: Seventy-nine patients with CNI-dependent primary membranous nephropathy (PMN) admitted between January 2018 and June 2023 were retrospectively enrolled in this study, and divided into three groups: the RTX group ( Results: After 12 months of treatment, among patients who did not achieve complete remission at baseline, the rates of newly achieved complete remission and CNI withdrawal were significantly higher in the RTX and CTX groups than in the TII group (all Conclusion: RTX and CTX are equally effective in treating CNI-dependent PMN, both significantly improving clinical complete remission rates and enabling successful CNI discontinuation. RTX shows advantages in achieving deeper immunological remission and better safety. TII can help reduce proteinuria and facilitate CNI tapering, making it suitable for patients intolerant to intensive immunosuppression or seeking a lower-risk treatment option.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.